Dr Reddy's expands collaboration with Amgen in India

Dr Reddy’s Laboratories (BSE: 500124), India’s third largest drugmaker, has expanded its strategic collaboration with Amgen, to market and distribute three of US biotech major Amgen’s (Nasdaq: AMGN) medicines in India in the therapy areas of oncology and osteoporosis.

Under the terms of the new collaboration deal, financial terms of which were not disclosed, Dr Reddy’s will commercialize in India Amgen’s: Xgeva (denosumab), a RANK ligand inhibitor which is approved in India for the prevention of skeletal related events in patients with advanced malignancies involving bone; Vectibix (panitumumab), approved in India for the treatment of adult patients with wild-type KRAS metastatic colorectal cancer; and Prolia (denosumab), approved in India for treatment of post-menopausal women with osteoporosis at high risk for fracture and also for treatment of increased bone mass in men with osteoporosis.

In 2015, Dr Reddy’s announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval of and launch Amgen’s Kyprolis (carfilzomib), Blincyto (blinatumomab) and Repatha (evolocumab) in India. The collaboration leverages the capabilities of both companies, combining Amgen's innovative therapies with Dr Reddy’s deep understanding of patient and physician needs in India.